C4 Therapeutics, Inc. (CCCC) Stock

C4 Therapeutics, Inc. (CCCC) is a Healthcare stock trading at $4.14 (as of 2026-06-18), with a market capitalization of $483.18M and a trailing P/E of -3.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutic candidates designed to degrade disease-related proteins. Its pipeline includes MonoDAC and BiDAC degraders, such as CFT7455 and CFT8634, in clinical trials for cancers and other diseases, and it also has earlier-stage programs; it works on these therapies for patient populations with targeted conditions.

Valuation — source: SEC EDGAR (first-party)
Price	$4.14
Market Cap	$483.18M
P/E Ratio	-3.5
EV / EBITDA	-3.3
Price / Book	1.84
Price / Sales	12.37
DCF Value (model)	$-16.52
DCF Upside vs Price	-499.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$35.95M
Net Margin	-292.1%
Return on Equity	-44.3%
Current Ratio	9.00
Revenue Growth (YoY)	1.0%
EPS Growth (YoY)	-16.4%
FCF Growth (YoY)	52.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.72 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-117.0%
vs Industry	-120.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	MORGAN STANLEY ($23.86M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Andrew J. Hirsch
Employees	110
Country	US
IPO Date	2020-10-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.